- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07946913
A Study to Evaluate the Efficacy and Safety of LP-003 Injection in Patients With Chronic Spontaneous Urticaria Who Remain Symptomatic Despite Treatment With H1 Antihistamines
A Multicenter, Randomized, Double-Blind, Active-Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of LP-003 Injection in Patients With Chronic Spontaneous Urticaria Who Remain Symptomatic Despite Treatment With H1 Antihistamines
This is a multicenter, randomized, double-blind, active-controlled Phase III clinical study to evaluate the safety and efficacy of LP-003 injection in patients with chronic spontaneous urticaria who remain symptomatic despite treatment with H1 antihistamines.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Fase
- Fase 3
Kontakter og plasseringer
Studiekontakt
- Navn: Jie Yang
- Telefonnummer: +8621-58372390
- E-post: yangj@longbiopharma.com
Studiesteder
-
-
-
Beijing, Kina
- Peking Union Medical College Hospital
-
Ta kontakt med:
- Yuxiang Zhi
- Telefonnummer: +8610-69151188
- E-post: yuxiang_zhi@126.com
-
Shenyang, Kina
- The First Affiliated Hospital of China Medical University
-
Ta kontakt med:
- Xinghua Gao
- Telefonnummer: +8624-83282524
- E-post: Gaobarry@hotmail.com
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Have the capacity to understand the study and voluntarily signs the informed consent form (ICF);
- Male or female participant must be 12 to 75 years old at the time of ICF signature;
- Duration of chronic spontaneous urticaria (CSU) ≥ 6 months prior to screening;
- Presence of pruritus and wheals for at least 6 consecutive weeks before screening despite treatment with H1-AH;
- Participants have been on a stable dose of second-generation H1-AH as specified in the protocol for ≥2 weeks prior to randomization and within the 7 days before randomization, the UAS7( range 0-42) ≥16 and ISS7(range 0-21) ≥8;
- Participants must not miss UAS scores for more than one day within the 7 days prior to randomization, and are willing and able to complete daily symptom diaries during the study period.
- Female participants of childbearing potential, and male participants (and their female partners), must use one or more effective contraceptive measures from the screening period until at least 6 months after the last administration of investigational product. Participants must have no plans for pregnancy, sperm donation or oocyte donation from screening until at least 6 months after the last dose of investigational product.
Exclusion Criteria:
- The subject has a primary or sole trigger for chronic urticaria (chronic Induced urticaria), including artificial urticaria (Symptomatic Dermographism), cold, heat, sun, pressure, delayed pressure, water, cholinergic, or contact urticaria;
- Other medical conditions accompanied by symptoms of urticaria or angioedema including, but not limited to, urticarial vasculitis, mastocytosis, pigmented urticaria, erythema multiforme, , hereditary or acquired angioedema, etc;
- Any other dermatologic condition with chronic itching, such as atopic dermatitis, bullous pemphigoid, dermatitis herpetiformis, senile pruritus or psoriasis, which in the judgment of the Investigator may affect the evaluation of the study and the results of the study;
- Body weight < 40 kg
- Not enough washing-out period for previous therapy before randomization.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Trippel
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: LP-003 group
Participants received LP-003 subcutaneously during the 48-week treatment period |
s.c. injection |
|
Aktiv komparator: Omalizumab group
Participants received omalizumab subcutaneously during the 48-week treatment period |
s.c. injection |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change from baseline in weekly Urticaria Activity Score (UAS7) at week 12
Tidsramme: Week 12
|
The UAS7 is a composite score derived from the ISS7 and the HSS7, i.e., the sum of ISS7 and HSS7, ranging from 0 to 42 points. UAS7 = 0 indicates complete resolution of urticaria. |
Week 12
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change from baseline in UAS7 at each assessment visit (excluding Week 12)
Tidsramme: up to approximately 56 weeks
|
up to approximately 56 weeks
|
|
|
The proportion of participants with UAS7 = 0 at each assessment visit
Tidsramme: up to approximately 56 weeks
|
up to approximately 56 weeks
|
|
|
The proportion of participants with UAS7 ≤ 6at each assessment visit
Tidsramme: up to approximately 56 weeks
|
up to approximately 56 weeks
|
|
|
Change From Baseline in weekly hives severity score (HSS7) at each assessment visit.
Tidsramme: up to approximately 56 weeks
|
The HSS7 is the sum of daily HSS scores over the 7 days prior to the visit, ranging from 0 to 21 points. HSS7 = 0 indicates complete resolution of hives. |
up to approximately 56 weeks
|
|
Change From Baseline in weekly itch severity score ( ISS7) at each assessment visit.
Tidsramme: Time Frame: up to approximately 56 weeks
|
The ISS7 is the sum of daily ISS scores over the 7 days prior to the visit, ranging from 0 to 21 points. ISS7 = 0 indicates complete resolution of itch. |
Time Frame: up to approximately 56 weeks
|
|
Change From Baseline in weekly angloedema activity score (AAS7) at each assessment visit.
Tidsramme: Time Frame: up to approximately 56 weeks
|
The AAS7 is the sum of the daily AAS scores over the 7 days prior to the visit, ranging from 0 to 105 points. AAS7 = 0 indicates no angioedema. |
Time Frame: up to approximately 56 weeks
|
|
Change From Baseline in Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL) at each assessment visit
Tidsramme: up to approximately 56 weeks
|
The scale consists of 23 items. Each item is scored from 1 to 5 points. The total score is transformed to a scale ranging from 0 to 100, with higher scores indicating a greater impact of the disease on patients' quality of life |
up to approximately 56 weeks
|
|
The incidence of adverse events during the study
Tidsramme: up to approximately 56 weeks
|
Incidence and severity of AE from first dose to end of study are recorded |
up to approximately 56 weeks
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Xinghua Gao, First Hospital of China Medical University
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Patologiske prosesser
- Kronisk sykdom
- Sykdomsattributter
- Sykdommer i immunsystemet
- Overfølsomhet, Umiddelbar
- Overfølsomhet
- Hudsykdommer
- Urticaria
- Hudsykdommer, vaskulære
- Patologiske tilstander, tegn og symptomer
- Hud- og bindevevssykdommer
- Kronisk urtikaria
- Aminosyrer, peptider og proteiner
- Proteiner
- Antistoffer, monoklonalt, humanisert
- Antistoffer, monoklonalt
- Antistoffer
- Immunoglobuliner
- Immunoproteiner
- Blodproteiner
- Serumglobuliner
- Globuliner
- Antistoffer, anti-idiotypisk
- Omalizumab
Andre studie-ID-numre
- P10-LP003-14
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .